HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

PHR

Phreesia, Inc.

Healthcare — Health Information Services

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It offers solutions including appointment optimization and referral management using AI-enabled workflows; and AI-based smart answering solution patient communications supported by voice and messaging solutions; integrated payment solutions embedded in intake and post-visit workflows, and financing solutions that enable healthcare organizations to accelerate cash collections while offering flexible payment options to patients; and digital intake and clinical data capture, patient engagement and activation tools, and measurement and analytics solutions. It also offers PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, which are on-site kiosks. The company serves a range of healthcare organizations including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest and not-for-profit and other organizations. Phreesia, Inc. was incorporated in 2005 and is based in Wilmington, Delaware.

Buy 2.0 / 5 17 analysts
$10.36
+$0.03 (+0.29%)
Target: $13.94 (34.6%)

Price History

52-Week Range
Sign in to add PHR to a watchlist or set price alerts.

Fundamentals

Market Cap$663.24M
P/E Ratio (TTM)67.06
Forward P/E6.68
EPS (TTM)$0.16
Dividend Yield-
Profit Margin1.85%
Revenue Growth12.90%
ROE2.86%
Debt/Equity25.78
Recommendation Buy 2.0
Analyst Target$13.94
Analysts17
Next Earnings Sep 2, 2026 AMC
Indexes -

Technical Indicators

RSI (14)45.7
Beta0.87
SMA 20$10.68
SMA 40$10.13
52-Week High$32.76
52-Week Low$7.77
50-Day Avg$10.00
200-Day Avg$13.66
Avg Volume899.4K
Volume711.1K

Performance Analysis

NEUTRAL

PHR presents a mixed picture with both positive and negative indicators.

~ Trading at 10% of its 52-week range.
~ RSI at 45.7 is in neutral territory.
- P/E of 67.1 is elevated — the market expects high growth or it may be overvalued.
~ Modest revenue growth of 12.9% year-over-year.
+ Wall Street consensus is "Buy" from 17 analysts.
+ Average analyst target of $13.94 implies 34.6% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Aug 01, 2026 04:15 UTC

Back to Screener Export Report